has announced the launch of Pomalidomide Capsules, a generic version of Pomalyst, in the US market.
This product, developed in partnership with Breckenridge Pharmaceutical, Inc., is indicated for the treatment of adult patients with multiple myeloma and AIDS-related Kaposi sarcoma.
Pomalidomide Capsules are available in strengths of 1mg, 2mg, 3mg, and 4mg and are distributed through specialty pharmacies and clinics. The estimated sales for Pomalidomide in the US for the year ending September 2025 was approximately $3.2 billion. Natco has indicated that it holds 180 days of shared exclusivity for this product as per FDA guidelines.
Rajeev Nannapaneni, Vice Chairman and Chief Executive Officer of NATCO Pharma, said, “The launch highlights our commitment to our mission of making specialty medicines accessible to all the patients worldwide. We look forward to bringing more such complex and specialty products to the market in the coming years.”
Natco Pharma shares ended 3 per cent lower on the NSE on Monday at ₹956.25.
(This article was generated using AI and vetted by a journalist)